Verastem (VSTM) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.65, -6.28% vs the prior close of $9.23.
- Volume 6.09M shares, 1.9x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
VSTM slides 6.3% to $8.65 on 1.9x normal volume. Closed at $8.65, -6.28% vs the prior close of $9.23. Day range $8.53–$9.37, opened at $9.30.
VSTM daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — VSTM slides 6.3% to $8.65 on 1.9x normal volume
- Closed at $8.65, -6.28% vs the prior close of $9.23. Day range $8.53–$9.37, opened at $9.30.
- Volume was 6.09M shares, 1.9x its 50-day average of 3.28M — unusually heavy trading.
- Price is +13.6% vs its 50-day average ($7.61) and +42.9% vs its 200-day average ($6.05).
- 52-week range $3.43–$10.82; today's close sits at 71% of that range, 20.1% below the 52-week high.
Oct 15, 2026 — VSTM jumps 19.7% to $9.23, a 6-month high on 5.7x normal volume
- Closed at $9.23, +19.71% vs the prior close of $7.71. Day range $7.77–$9.73, opened at $8.04.
- Volume was 16.94M shares, 5.7x its 50-day average of 2.97M — unusually heavy trading.
- Price is +22.1% vs its 50-day average ($7.56) and +52.7% vs its 200-day average ($6.05).
- 52-week range $3.43–$10.82; today's close sits at 78% of that range, 14.7% below the 52-week high.
Oct 14, 2026 — VSTM jumps 3.5% to $7.71 on 14.5x normal volume
- Closed at $7.71, +3.49% vs the prior close of $7.45. Day range $6.70–$8.96, opened at $8.00.
- Volume was 33.75M shares, 14.5x its 50-day average of 2.33M — unusually heavy trading.
- Price is +2.9% vs its 50-day average ($7.49) and +27.7% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 58% of that range, 28.7% below the 52-week high.
- SEC filings that day: 8-K, 424B5, 424B5, 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 13, 2026 — VSTM slides 9.7% to $7.45
- Closed at $7.45, -9.70% vs the prior close of $8.25. Day range $7.45–$8.20, opened at $8.15.
- Volume was 3.43M shares, 1.5x its 50-day average of 2.29M.
- Price is -0.1% vs its 50-day average ($7.45) and +23.3% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 54% of that range, 31.1% below the 52-week high.
Oct 12, 2026 — VSTM dips 1.6% to $8.25
- Closed at $8.25, -1.55% vs the prior close of $8.38. Day range $8.08–$8.60, opened at $8.42.
- Volume was 3.58M shares, 1.6x its 50-day average of 2.26M.
- Price is +11.2% vs its 50-day average ($7.42) and +36.5% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 65% of that range, 23.8% below the 52-week high.
Oct 9, 2026 — VSTM jumps 3.3% to $8.38, a 6-month high
- Closed at $8.38, +3.33% vs the prior close of $8.11. Day range $7.98–$8.58, opened at $8.12.
- Volume was 2.97M shares, 1.3x its 50-day average of 2.22M.
- Price is +13.7% vs its 50-day average ($7.37) and +38.7% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 67% of that range, 22.6% below the 52-week high.
Oct 8, 2026 — VSTM dips 1.9% to $8.11
- Closed at $8.11, -1.93% vs the prior close of $8.27. Day range $7.72–$8.28, opened at $8.20.
- Volume was 3.05M shares, 1.4x its 50-day average of 2.21M.
- Price is +10.7% vs its 50-day average ($7.32) and +34.3% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 63% of that range, 25.0% below the 52-week high.
Oct 7, 2026 — VSTM jumps 6.7% to $8.27 on 1.8x normal volume
- Closed at $8.27, +6.71% vs the prior close of $7.75. Day range $7.65–$8.36, opened at $7.77.
- Volume was 3.93M shares, 1.8x its 50-day average of 2.16M — unusually heavy trading.
- Price is +13.6% vs its 50-day average ($7.28) and +37.0% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 65% of that range, 23.6% below the 52-week high.
Oct 6, 2026 — VSTM slides 3.1% to $7.75
- Closed at $7.75, -3.12% vs the prior close of $8.00. Day range $7.70–$8.18, opened at $8.08.
- Volume was 2.51M shares, 1.2x its 50-day average of 2.15M.
- Price is +7.0% vs its 50-day average ($7.24) and +28.4% vs its 200-day average ($6.03).
- 52-week range $3.43–$10.82; today's close sits at 58% of that range, 28.4% below the 52-week high.
Oct 5, 2026 — VSTM jumps 3.9% to $8.00
- Closed at $8.00, +3.90% vs the prior close of $7.70. Day range $7.52–$8.10, opened at $7.74.
- Volume was 2.22M shares, 1.0x its 50-day average of 2.16M.
- Price is +11.0% vs its 50-day average ($7.21) and +32.6% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 62% of that range, 26.1% below the 52-week high.
Oct 2, 2026 — VSTM dips 2.5% to $7.70 on 1.9x normal volume
- Closed at $7.70, -2.53% vs the prior close of $7.90. Day range $7.52–$8.02, opened at $7.95.
- Volume was 4.07M shares, 1.9x its 50-day average of 2.12M — unusually heavy trading.
- Price is +7.4% vs its 50-day average ($7.17) and +27.5% vs its 200-day average ($6.04).
- 52-week range $3.43–$10.82; today's close sits at 58% of that range, 28.8% below the 52-week high.
VSTM latest news & SEC filings
Every SEC filing by or about VSTM in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Oct 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Paterson Dan received an award of 106,893 shares on Sep 30, 2026; now holds 696,833
- Paterson Dan sold 44,121 shares at $8.00 (≈$352.97K) on Oct 1, 2026; now holds 652,712
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Calkins Daniel received an award of 8,333 shares on Sep 30, 2026; now holds 126,347
- Calkins Daniel sold 2,566 shares at $8.00 (≈$20.53K) on Oct 1, 2026; now holds 123,781
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Calkins Daniel sold 55 shares at $7.70 (≈$424) on Sep 21, 2026; now holds 118,014
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $40.08M (prior year $2.14M) (+1775.4% vs Jun 30, 2025)
- Net income: -$34.67M (prior year -$25.93M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.35 (prior year -$0.62) (loss narrowed vs Jun 30, 2025)
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Paterson Dan sold 1,302 shares at $5.81 (≈$7.56K) on Aug 3, 2026
- Paterson Dan sold 1,302 shares at $5.81 (≈$7.56K) on Aug 3, 2026
- Paterson Dan sold 1,302 shares at $5.81 (≈$7.56K) on Aug 3, 2026
- Paterson Dan sold 1,302 shares at $5.81 (≈$7.56K) on Aug 3, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade VSTM
- Last results release: Oct 14, 2026 (8-K Item 2.02). Previous ones: Aug 6, 2026, Feb 4, 2026, Nov 4, 2025. Based on that rhythm, the next report is likely around Jan 13, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.40% (largest 19.7%). That is a volatile stock.
- Liquidity: about 5.03M shares (≈$43.48M) trade per day on average.
- 52-week position: $8.65 vs a range of $3.43–$10.82 (71% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Daniel Calkins sold 55 shares on Sep 21, 2026.
- Latest filings: 8-K Oct 14, 2026; 8-K Oct 14, 2026; 8-K Aug 7, 2026.
- Share count: 90.56M shares outstanding (Aug 3, 2026), +47.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
VSTM market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 9.30 | 9.37 | 8.53 | 8.65 | 6.09M |
| Oct 15, 2026 | 8.04 | 9.73 | 7.77 | 9.23 | 16.96M |
| Oct 14, 2026 | 8.00 | 8.96 | 6.70 | 7.71 | 33.75M |
| Oct 13, 2026 | 8.15 | 8.20 | 7.45 | 7.45 | 3.43M |
| Oct 12, 2026 | 8.42 | 8.60 | 8.08 | 8.25 | 3.58M |
| Oct 9, 2026 | 8.12 | 8.58 | 7.98 | 8.38 | 2.97M |
| Oct 8, 2026 | 8.20 | 8.28 | 7.72 | 8.11 | 3.05M |
| Oct 7, 2026 | 7.77 | 8.36 | 7.65 | 8.27 | 3.93M |
| Oct 6, 2026 | 8.08 | 8.18 | 7.70 | 7.75 | 2.51M |
| Oct 5, 2026 | 7.74 | 8.10 | 7.52 | 8.00 | 2.22M |
| Oct 2, 2026 | 7.95 | 8.02 | 7.52 | 7.70 | 4.07M |
| Oct 1, 2026 | 8.00 | 8.18 | 7.74 | 7.90 | 1.76M |
| Sep 30, 2026 | 7.98 | 8.40 | 7.92 | 8.05 | 1.57M |
| Sep 29, 2026 | 7.78 | 8.12 | 7.56 | 7.92 | 2.68M |
| Sep 28, 2026 | 7.59 | 7.78 | 7.39 | 7.77 | 1.26M |
| Sep 25, 2026 | 7.86 | 7.89 | 7.67 | 7.74 | 1.06M |
| Sep 24, 2026 | 8.10 | 8.20 | 7.71 | 7.80 | 1.84M |
| Sep 23, 2026 | 8.37 | 8.40 | 7.85 | 8.18 | 1.94M |
| Sep 22, 2026 | 8.04 | 8.65 | 8.00 | 8.37 | 3.06M |
| Sep 21, 2026 | 7.54 | 8.04 | 7.50 | 7.99 | 2.80M |
About Verastem
Verastem (VSTM) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEEDHAM, MA. State of incorporation: MA. Fiscal year ends December 31. SEC CIK 1526119.
VSTM board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael P Bailey | Director | May 27, 2026 |
| Paul A. Bunn | Director | May 26, 2026 |
| Robert E. Gagnon | Director | Dec 18, 2025 |
| John Johnson | Director | May 26, 2026 |
| Anil Kapur | Director | May 26, 2026 |
| Michael Kauffman | President of Development | Jan 8, 2026 |
| Dan Paterson | President and CEO | Aug 5, 2026 |
| Michelle Robertson | Director | May 26, 2026 |
| Eric K Rowinsky | Director | May 26, 2026 |
| Brian M Stuglik | Director | May 26, 2026 |
| Karin Anna Tollefson | Director | May 26, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Daniel Calkins | Chief Financial Officer | Sep 23, 2026 |
| Michael Kauffman | President of Development | Jan 8, 2026 |
| Dan Paterson | President and CEO | Aug 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 21, 2026 | Daniel Calkins | Sale | 55 | $7.70 |
| Sep 21, 2026 | Daniel Calkins | Sale | 55 | $7.70 |
| Sep 21, 2026 | Daniel Calkins | Sale | 55 | $7.70 |
| Sep 21, 2026 | Daniel Calkins | Sale | 55 | $7.70 |
| Aug 3, 2026 | Dan Paterson | Sale | 1,302 | $5.81 |
| Aug 3, 2026 | Dan Paterson | Sale | 1,302 | $5.81 |
| Aug 3, 2026 | Dan Paterson | Sale | 1,302 | $5.81 |
| Aug 3, 2026 | Dan Paterson | Sale | 1,302 | $5.81 |
| Jun 22, 2026 | Daniel Calkins | Sale | 4,032 | $4.18 |
| Jun 22, 2026 | Daniel Calkins | Sale | 57 | $4.13 |
| Jun 22, 2026 | Daniel Calkins | Sale | 4,032 | $4.18 |
| Jun 22, 2026 | Daniel Calkins | Sale | 57 | $4.13 |
| Jun 22, 2026 | Daniel Calkins | Sale | 4,032 | $4.18 |
| Jun 22, 2026 | Daniel Calkins | Sale | 57 | $4.13 |
| Jun 22, 2026 | Daniel Calkins | Sale | 4,032 | $4.18 |
VSTM financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-209.47M | -3.02 | $-137.51M |
| Dec 31, 2024 | $10.00M | $-130.64M | -3.66 | $-104.77M |
| Dec 31, 2023 | — | $-87.37M | -3.96 | $-86.46M |
| Dec 31, 2022 | $2.60M | $-73.81M | -4.57 | $-63.67M |
| Dec 31, 2021 | $2.05M | $-71.20M | -4.90 | $-53.50M |
Latest balance sheet: total assets $206.51M, total liabilities $156.53M, cash $136.35M (as of Jun 30, 2026).
VSTM earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 14, 2026 | 8-K Item 2.02 (results) | $7.71 |
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.91 |
| Feb 4, 2026 | 8-K Item 2.02 (results) | $6.79 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $7.91 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $5.34 |
| Feb 2, 2023 | 8-K Item 2.02 (results) | — |
| Aug 8, 2022 | 8-K Item 2.02 (results) | — |
| Mar 28, 2022 | 8-K Item 2.02 (results) | — |
| Aug 10, 2020 | 8-K Item 2.02 (results) | — |
| Apr 27, 2020 | 8-K Item 2.02 (results) | — |
| Feb 28, 2020 | 8-K Item 2.02 (results) | — |
| Oct 29, 2019 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on VSTM
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.